Protozoal DNA-associated enzymes

Protozoal DNA-associated enzymes represent a functional group of essential proteins, including topoisomerases (notably topoisomerase II), endonucleases, and exonucleases, that are critical for the maintenance and replication of the protozoan genome (DrugBank, DB00738). These enzymes are the primary hypothesized targets for aromatic diamidine drugs such as pentamidine, which are employed in the treatment of serious parasitic infections including Pneumocystis pneumonia, leishmaniasis, and African trypanosomiasis (StatPearls, 2024). The drugs typically act by binding to the minor groove of DNA, particularly in AT-rich regions, which sterically hinders the access and activity of these DNA-associated enzymes, thereby disrupting DNA, RNA, and protein synthesis (PubMed, 2004). This interference often leads to the disintegration of kinetoplast DNA and the inhibition of nuclear metabolism, ultimately resulting in the death of the parasite (Frontiers in Pharmacology, 2015). Despite their efficacy, targeting these enzymes is associated with significant clinical challenges, including severe systemic toxicities such as nephrotoxicity, sudden hypotension, and pancreatic islet cell damage (Mayo Clinic, 2025).

Other names

DNA-associated enzymesProtozoan DNA-associated enzymesKinetoplast DNA-associated enzymes

Inhibition of DNA-associated enzymes through minor groove binding of DNA, which sterically hinders enzyme activity and disrupts replication and transcription.